Premium
Study of plasma‐derived miRNAs mimic differences in Huntington's disease brain
Author(s) -
Hoss Andrew G.,
Lagomarsino Valenti.,
Frank Samuel,
Hadzi Tiffany C.,
Myers Richard H.,
Latourelle Jeanne C.
Publication year - 2015
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.26457
Subject(s) - huntington's disease , neuroscience , disease , microrna , degenerative disease , central nervous system disease , medicine , biology , psychology , genetics , gene
Background Biomarkers for Huntington's disease progression could accelerate therapeutic developments and improve patient care. Brain microRNAs relating to clinical features of Huntington's disease may represent a potential Huntington's disease biomarker in blood. Objective This study was undertaken to examine candidate microRNAs in plasma to determine whether changes observed in HD brains are detectable in peripheral samples. Methods Four microRNAs from 26 manifest Huntington's disease, four asymptomatic Huntington's disease gene carriers, and eight controls were quantified in plasma using reverse transcription quantitative polymerase chain reaction. Linear regression was used to assess microRNA levels across control, asymptomatic gene carriers, and manifest patients. Results miR‐10b‐5p ( P = 0.0068) and miR‐486‐5p ( P = 0.044) were elevated in Huntington's disease plasma. miR‐10b‐5p was decreased in asymptomatic gene carriers as compared with patients with Huntington's disease ( P = 0.049), but no difference between asymptomatic gene carriers and healthy controls was observed ( P = 0.24). Conclusions These findings suggest that microRNA changes observed in Huntington's disease brain may be detectable in plasma and have potential clinical utility. © 2015 International Parkinson and Movement Disorder Society